Insider Selling: Vernalis plc (VER) Insider Sells 27,233 Shares of Stock
Vernalis plc (LON:VER) insider David Mackney sold 27,233 shares of the company’s stock in a transaction dated Wednesday, October 12th. The shares were sold at an average price of GBX 39 ($0.48), for a total transaction of £10,620.87 ($13,144.64).
Shares of Vernalis plc (LON:VER) traded up 1.59% during mid-day trading on Thursday, hitting GBX 40.00. 363,589 shares of the company were exchanged. The company’s market capitalization is GBX 210.48 million. Vernalis plc has a 12-month low of GBX 31.00 and a 12-month high of GBX 75.00. The firm has a 50 day moving average of GBX 42.45 and a 200 day moving average of GBX 44.84.
A number of research firms have issued reports on VER. Shore Capital restated a “house stock” rating on shares of Vernalis plc in a research report on Tuesday, July 19th. Canaccord Genuity reiterated a “buy” rating and issued a GBX 84 ($1.04) price target on shares of Vernalis plc in a research report on Tuesday, July 19th. Panmure Gordon reiterated a “buy” rating and issued a GBX 76 ($0.94) price target on shares of Vernalis plc in a research report on Thursday, September 29th. Stifel Nicolaus reiterated a “buy” rating and issued a GBX 99 ($1.23) price target on shares of Vernalis plc in a research report on Thursday, September 29th. Finally, N+1 Singer reiterated a “hold” rating and issued a GBX 46 ($0.57) price target on shares of Vernalis plc in a research report on Thursday, September 29th. One research analyst has rated the stock with a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of GBX 73 ($0.90).
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/insider-selling-vernalis-plc-ver-insider-sells-27233-shares-of-stock.html
About Vernalis plc
Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine.
Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with MarketBeat.com's FREE daily email newsletter.